생체흡수성 스텐트 시장 : 소재별, 제품 유형별, 분해 시간별, 용도별, 최종사용자별, 유통 채널별 - 시장 예측(2026-2032년)

The Bioabsorbable Stents Market is projected to grow by USD 952.71 million at a CAGR of 6.63% by 2032.

Bioabsorbable Stents Market Introduction

Bioabsorbable stents, also known as bioresorbable vascular scaffolds, are designed to provide temporary vessel support after percutaneous coronary intervention and then gradually degrade, potentially restoring vasomotion and reducing the long-term presence of permanent metallic implants. The category remains clinically important because cardiovascular disease continues to be the world's leading cause of death, with the World Health Organization estimating about 17.9 million deaths annually from cardiovascular conditions.

The bioabsorbable stents market is shaped by a clear evidence threshold. Early enthusiasm moderated after first-generation polymeric scaffolds showed higher risks of scaffold thrombosis in some studies, and a leading first-generation scaffold was withdrawn from global commercial availability in 2017. Current growth is therefore driven less by broad replacement of contemporary drug-eluting stents and more by targeted innovation in thinner struts, improved deployment protocols, magnesium-based platforms, advanced imaging guidance, and rigorously selected patient populations.

Transformative Shifts in the Bioabsorbable Stents Landscape

The bioabsorbable stents landscape is shifting from concept-led commercialization toward evidence-led specialization. Developers are prioritizing thinner scaffold profiles, improved radial strength, controlled degradation kinetics, and drug-elution consistency to address the safety lessons of first-generation devices. This transition aligns with cardiology's broader preference for proven clinical outcomes over device novelty, especially in coronary artery disease treatment.

Regulation is another major transformative force. Europe's Medical Device Regulation has raised expectations for clinical evidence and post-market surveillance, while the United States maintains a high bar for premarket approval of coronary scaffold technologies. In Asia-Pacific, local innovation in China, India, Japan, and South Korea is increasing competitive intensity, particularly where domestic manufacturing policies, rising procedure capacity, and large coronary artery disease burdens support clinical research and technology localization.

Cumulative Impact of Artificial Intelligence on Bioabsorbable Stents

Artificial intelligence is influencing bioabsorbable stents across the full value chain, from biomaterial design to real-world evidence generation. AI-assisted simulation can help evaluate scaffold geometry, radial strength, degradation behavior, and drug-release profiles before extensive bench or animal testing. This can shorten iteration cycles while improving the probability that designs meet safety, deliverability, and procedural performance requirements.

In clinical practice, AI-enabled intravascular imaging and angiographic analysis can support lesion assessment, vessel sizing, scaffold expansion, and post-procedure optimization. These factors are particularly important for bioabsorbable scaffolds because implantation technique and patient selection strongly affect outcomes. Machine learning applied to registries, claims data, and follow-up imaging can also strengthen post-market surveillance by detecting safety signals earlier, refining indications, and improving evidence quality for bioresorbable vascular scaffolds.

Key Regional Insights for Bioabsorbable Stents

Asia-Pacific is emerging as a strategic arena for bioabsorbable stents because of high cardiovascular disease prevalence, expanding catheterization infrastructure, and strong domestic device ecosystems in China, India, Japan, and South Korea. China's regulatory modernization and hospital investment support local clinical evaluation, while India's large patient base and price-sensitive market create demand for cost-efficient scaffold platforms with clear clinical value. Japan and South Korea add advanced imaging adoption, rigorous quality expectations, and strong clinical research capabilities, making the region important for next-generation bioresorbable vascular scaffold development.

North America remains a premium evidence-generation region, led by the United States and Canada, but adoption is constrained by strict regulatory standards and limited routine use of coronary bioresorbable scaffolds after first-generation safety concerns. Europe has historically been important for CE-marked technologies, yet the EU Medical Device Regulation has intensified clinical documentation, post-market follow-up, and safety surveillance requirements. Latin America, led by Brazil and Mexico, presents selective opportunities in tertiary cardiac centers where private healthcare access and specialist interventional cardiology capacity are stronger. The Middle East, especially GCC countries, is investing in advanced hospital infrastructure, cardiovascular programs, and medical tourism, while Africa remains a longer-term opportunity due to uneven cath lab access, affordability constraints, and the need for scalable cardiovascular care pathways.

Key Group Insights for Bioabsorbable Stents

ASEAN offers a mixed but promising environment for bioabsorbable stents, with Singapore, Malaysia, Thailand, Indonesia, and Vietnam showing different levels of reimbursement maturity, hospital capacity, and regulatory readiness. Premium bioresorbable vascular scaffolds are most likely to gain traction first in advanced urban cardiac centers where imaging-guided PCI, trained interventional cardiologists, and structured follow-up programs are available. ASEAN demand is also shaped by the region's rising burden of diabetes, hypertension, and ischemic heart disease, which increases the need for durable cardiovascular care models.

The GCC is positioned as a high-value adoption cluster due to continued investment in tertiary hospitals, cardiovascular centers, and medical tourism infrastructure. The European Union is central for regulatory credibility, but MDR compliance increases the importance of clinical evidence, post-market follow-up, and quality management systems. BRICS countries combine large coronary disease burdens with growing domestic manufacturing capabilities, making them important for localized production, clinical trials, and affordability-focused innovation. G7 markets remain critical for scientific validation, reimbursement evidence, and guideline influence, while NATO countries increasingly emphasize medical supply-chain resilience, trusted sourcing, and continuity of access for critical health technologies.

Key Country Insights for Bioabsorbable Stents

The United States is the most influential country for clinical validation, reimbursement evidence, regulatory credibility, and investor confidence, although scrutiny remains high after first-generation scaffold safety concerns. Canada follows a conservative, evidence-based adoption model shaped by health technology assessment and provincial procurement priorities, while Mexico offers opportunities through private hospitals, urban specialty centers, and cross-border specialty care. Brazil is Latin America's primary interventional cardiology market and a key site for regional commercialization, supported by a large cardiovascular disease burden and established tertiary hospital networks.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced PCI capacity with strong health technology assessment discipline, physician training standards, and post-market evidence expectations, while Russia presents opportunities tempered by geopolitical, procurement, and supply-chain uncertainty. China is scaling domestic cardiovascular innovation through hospital expansion, regulatory reform, and local device development, while India offers a large patient base and cost-sensitive demand that favors differentiated clinical value and affordability. Japan maintains strict quality expectations through PMDA review and careful clinical adoption, Australia supports evidence-led specialty use through advanced cardiac centers, and South Korea contributes strong medtech manufacturing, hospital digitization, intravascular imaging use, and clinical research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should focus on clinically differentiated indications rather than broad substitution of contemporary drug-eluting stents. The strongest strategies will pair improved scaffold design with imaging-guided implantation protocols, physician training, and long-term follow-up data that directly address scaffold thrombosis, restenosis, target lesion failure, and late adverse events.

Organizations should invest in AI-enabled design validation, real-world evidence platforms, and registry-based safety monitoring. Commercial teams should prioritize markets with advanced cath lab infrastructure, predictable reimbursement, experienced interventional cardiology networks, and regulators receptive to robust clinical evidence. Partnerships with hospitals, academic centers, and local manufacturers can improve trial recruitment, localization, training, and market access, especially in Asia-Pacific, GCC countries, and selected BRICS economies.

Research Methodology

This executive summary is built on a structured secondary research approach using verified sources, including public health data from the World Health Organization, regulatory information from agencies such as the U.S. FDA and European authorities, peer-reviewed clinical literature on bioresorbable vascular scaffolds, and publicly available product and regulatory disclosures. The assessment emphasizes documented clinical, regulatory, technological, and commercial developments rather than speculative market claims.

The analysis applies triangulation across clinical outcomes, reimbursement dynamics, regional healthcare infrastructure, technology readiness, regulatory requirements, and competitive positioning. Particular attention is given to lessons from first-generation bioabsorbable stents, current evidence requirements, post-market surveillance expectations, and the role of AI, imaging, and biomaterials innovation in improving next-generation bioabsorbable stent performance.

Conclusion

The bioabsorbable stents market is entering a more disciplined phase defined by clinical evidence, patient selection, and technology refinement. While earlier devices exposed meaningful safety and adoption challenges, the underlying clinical rationale for temporary vascular scaffolding remains relevant where long-term metallic caging may be undesirable and where lesion characteristics support careful use.

Future success will depend on safer materials, thinner profiles, reliable degradation, AI-supported development, optimized implantation techniques, and high-quality post-market evidence. Stakeholders that align innovation with regulatory expectations, interventional cardiology workflows, physician training, and regional affordability realities will be best positioned to capture sustainable opportunities in the evolving bioabsorbable stents market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bioabsorbable Stents Market, by Material

• 7.1. Metal-based Bioabsorbable Stents
  • 7.1.1. Iron-based
  • 7.1.2. Magnesium-based
  • 7.1.3. Zinc-based Alloys
• 7.2. Polymer-based Bioabsorbable Stents
  • 7.2.1. Poly-L-lactic acid (PLLA)
  • 7.2.2. Polycaprolactone (PCL)
  • 7.2.3. Polydioxanone (PDO)
  • 7.2.4. Polyglycolic acid (PGA)

8. Bioabsorbable Stents Market, by Product Type

• 8.1. Drug-Eluting
• 8.2. Non-Drug-Eluting

9. Bioabsorbable Stents Market, by Degradation Time

• 9.1. 12-24 months
• 9.2. Less than 12 months
• 9.3. More than 24 months

10. Bioabsorbable Stents Market, by Application

• 10.1. Coronary Artery Disease (CAD)
• 10.2. Neurovascular Disease
• 10.3. Pediatric Applications
• 10.4. Peripheral Artery Disease (PAD)

11. Bioabsorbable Stents Market, by End User

• 11.1. Academic & Research Institutions
• 11.2. Ambulatory Surgical Centers
• 11.3. Cardiac Centers
• 11.4. Hospitals

12. Bioabsorbable Stents Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Bioabsorbable Stents Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Bioabsorbable Stents Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Bioabsorbable Stents Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Amaranth Medical, Inc.
• 17.3. Arterius Ltd
• 17.4. B. Braun SE
• 17.5. BIOTRONIK SE & Co. KG
• 17.6. Boston Scientific Corporation
• 17.7. Cardionovum GmbH
• 17.8. Elixir Medical Corporation
• 17.9. ELLA - CS, s.r.o.
• 17.10. JW Medical Systems Ltd. Biosensors International Group, Ltd.
• 17.11. Kaneka Corporation
• 17.12. Kyoto Medical Planning Co. Ltd.
• 17.13. Lepu Medical Technology Co. Ltd.
• 17.14. Meril Life Sciences
• 17.15. Microport Scientific Corporation
• 17.16. OrbusNeich Medical Group Holdings Limited
• 17.17. Q3 Medical Group
• 17.18. Reva Medical
• 17.19. SafeGuard Surgical, Inc.
• 17.20. Shandong Hua'an Biotechnology
• 17.21. Sino Medical Sciences Technology Inc.
• 17.22. Svelte Medical Systems Inc
• 17.23. Terumo Corporation
• 17.24. WEGO HEALTHCARE (SHENZHEN) CO., LTD
• 17.25. Zorion Medical Inc.